ClinicalTrials.gg
RecruitingNCT07711418ZENITH AD-2Updated Sep 8, 2026

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

A Phase 3 interventional study of Rezpegaldesleukin and Placebo in Moderate-to-Severe Atopic Dermatitis, sponsored by Nektar Therapeutics. Recruiting at 13 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Nektar Therapeutics · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
510
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Planned enrollment
59th of 544
510 · median 96
Started
2026
with 28 others
Phase 3
103 of 639
8 open now
Primary completion
2028-06
later than 87 of 115 live
Registered
632nd of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 59th largest by planned enrollment of the 544 interventional ones that give a count, is one of 29 that started in 2026, is one of 103 in phase 3, reaches primary completion later than 87 of the 115 other live ones, and was the 632nd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

72 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo.

The estimated participant overall duration is approximately 15 months.

03

Conditions studied

  • Moderate-to-Severe Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients, ≥ 12 years of age on the day of signing the form and weighing ≥ 40 kg prior to randomization at Baseline
  • Chronic atopic dermatitis (AD) defined as onset of AD signs and symptoms

    ≥ 12 months prior to Screening as determined by the Investigator through patient interview and/or review of medical history at the Screening Visit

  • Patients must meet the following AD severity criteria:
  • IGA score ≥ 3 (scale of 0 to 4) at Screening and Baseline
  • ≥ 10.0% of BSA involvement at Screening and Baseline
  • EASI ≥ 16.0 at Screening and Baseline
  • Are candidates for systemic therapy and have history, documented by a physician and/or the Investigator, of inadequate response to existing topical medications within 6 months preceding Screening, or history of intolerance to a topical therapy
  • Provide written, informed consent to participate in the study and follow the study procedures, including compliance with the use of highly effective

Exclusion criteria

Exclusion Criteria:

  • Are currently experiencing or have a history of concomitant skin conditions other than AD, including skin infection in the area affected by the patient's AD that requires treatment with systemic antimicrobial therapy
  • Are currently experiencing or have a history of unstable course of AD
  • History of chronic idiopathic urticaria at any time or urticaria from other causes within 4 weeks prior to randomization at the Baseline Visit.
  • Have a history of TCS use suggestive of a high risk for topical (TCS) withdrawal
  • Have received any of the following treatments at any time before Screening: aldesleukin; IL-2 analog; systemic biologic; oral JAKi; or any prior investigational agent for AD
  • Have a current or recent acute, active infection
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
510 participants (estimated)

Study arms

  • Experimental
    Blinded Induction Period: Rezpegaldesleukin every 2 weeks

    Rezpegaldesleukin every 2 weeks during the induction period

    Drug: Rezpegaldesleukin

  • Placebo comparator
    Blinded Induction Period: Placebo

    Placebo every 2 weeks during the induction period

    Drug: Placebo

  • Experimental
    Blinded Maintenance Period: Rezpegaldesleukin every 4 weeks

    Rezpegaldesleukin every 4 weeks during the maintenance period

    Drug: Rezpegaldesleukin

  • Experimental
    Blinded Maintenance Period: Rezpegaldesleukin every 12 weeks

    Rezpegaldesleukin every 12 weeks during the maintenance period

    Drug: Rezpegaldesleukin

  • Placebo comparator
    Blinded Maintenance Period: Placebo

    Placebo every 4 weeks during the maintenance period

    Drug: Placebo

  • Experimental
    Open-Label Escape

    Rezpegaldesleukin at a frequency determined by the investigator during the open-label escape

    Drug: Rezpegaldesleukin

Interventions

  • Pharmaceutical form: Injection solution Route of administration: subcutaneous

    Also known as: NKTR-358

  • DrugPlacebo

    Pharmaceutical form: Injection solution Route of administration: subcutaneous

06

What researchers measure

Primary outcomes

  1. US only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 and reduction ≥ 2 points from baseline at Week 24

    The IGA scale ranges from 0 to 4, with higher score indicating more severe disease.

    Time frame: Week 0 and Week 24

  2. Non-US regions only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 at Week 24

    The IGA scale ranges from 0 to 4, with higher score indicating more severe disease.

    Time frame: Week 0 and Week 24

  3. Non-US regions only: Number of participants with a ≥ 75% reduction in Eczema Area and Severity Index (EASI) score from baseline at Week 24 (EASI-75)

    The EASI scores range from 0 to 72, with higher scores indicating more severe atopic dermatitis.

    Time frame: Week 0 and Week 24

Secondary outcomes

  1. US only: Number of participants with a ≥ 75% reduction in EASI score from baseline at Week 24 (EASI-75)

    The EASI scores range from 0 to 72, with higher scores indicating more severe atopic dermatitis.

    Time frame: Week 0 and Week 24

  2. Number of participants with a ≥ 90% reduction in EASI score from baseline at Week 24 (EASI-90)

    The EASI scores range from 0 to 72, with higher scores indicating more severe atopic dermatitis.

    Time frame: Week 0 and Week 24

  3. Number of participants at week 6 achieving a 4-point or greater improvement in Itch numerical rating scale (NRS) in the subset of participants with a 4-point or greater Itch NRS at baseline

    The itch NRS goes from 0 to 10, with higher score indicating more severe itch.

    Time frame: Week 0 and Week 6

  4. Number of participants at week 24 achieving a 4-point or greater improvement in Itch numerical rating scale (NRS) in the subset of participants with a 4-point or greater Itch NRS at baseline

    The itch NRS goes from 0 to 10, with higher score indicating more severe itch.

    Time frame: Week 0 and Week 24

  5. Number of participants at week 6 achieving a 4-point or greater improvement in Skin Pain numerical rating scale (NRS) in the subset of participants with a 4-point or greater Skin Pain NRS at baseline

    The Skin Pain NRS goes from 0 to 10, with higher score indicating more severe pain.

    Time frame: Week 0 and Week 6

  6. Number of participants at week 24 achieving a 4-point or greater improvement in Skin Pain numerical rating scale (NRS) in the subset of participants with a 4-point or greater Skin Pain NRS at baseline

    The Skin Pain NRS goes from 0 to 10, with higher score indicating more severe pain.

    Time frame: Week 0 and Week 24

  7. Number of participants at week 6 achieving a 1.25-point or greater improvement in Atopic Dermatitis Sleep Scale Question 1 (ADSS Q1) in the subset of participants with a 1.25-point or greater ADSS Q1 at baseline

    The ADSS Q1 goes from 0 to 4, with higher score indicating more difficulty sleeping.

    Time frame: Week 0 and Week 6

  8. Number of participants at week 24 achieving a 1.25-point or greater improvement in ADSS Q1 in the subset of participants with a 1.25-point or greater ADSS Q1 at baseline

    The ADSS Q1 goes from 0 to 4, with higher score indicating more difficulty sleeping.

    Time frame: Week 0 and Week 24

  9. Change in Asthma Control Questionnaire-5 (ACQ-5) score from baseline at Week 24 in the subpopulation of patients with a 0.5-point or greater ACQ-5 at baseline

    The ACQ-5 goes from 0 to 6, with higher score indicating worse asthma control.

    Time frame: Week 0 and Week 24

  10. Number of participants at week 24 achieving a 0.5-point or greater improvement in ACQ-5 in the subset of participants with a 0.5-point or greater ACQ-5 at baseline

    The ACQ-5 goes from 0 to 6, with higher score indicating worse asthma control.

    Time frame: Week 0 and Week 24

  11. Change in Sino-Nasal Outcome Test (SNOT-22) score from baseline at Week 24 in the subpopulation of patients with an 8.9-point or greater SNOT-22 at baseline

    The SNOT-22 scores range from 0 to 110, with a higher score indicating more severe symptoms

    Time frame: Week 0 and Week 24

  12. Number of participants at Week 24 achieving a 8.9-point or greater reduction from baseline in SNOT-22 in the subpopulation of patients with an 8.9-point or greater SNOT-22 at baseline

    The SNOT-22 scores range from 0 to 110, with a higher score indicating more severe symptoms

    Time frame: Week 0 and Week 24

  13. Number of participants at week 24 achieving an Adapted Investigator's Global Assessment (aIGA) response of 0 or 1

    The aIGA scale ranges from 0 to 1, with a lower score indicating improvement in atopic dermatitis.

    Time frame: Week 0 and Week 24

  14. Number of participants with treatment emergent adverse events (TEAEs)

    Time frame: Through participant study completion, approximately Week 56

  15. Number of participants with treatment emergent serious adverse events

    Time frame: Through participant study completion, approximately Week 56

  16. Number of participants with treatment related serious adverse events

    Time frame: Through participant study completion, approximately Week 56

  17. Number of participants with treatment emergent adverse events of special interest

    Time frame: Through participant study completion, approximately Week 56

  18. Number of participants with treatment related adverse events of special interest

    Time frame: Through participant study completion, approximately Week 56

  19. Number of participants with TEAEs leading to treatment discontinuation

    Time frame: Through participant study completion, approximately Week 56

  20. Number of participants with TEAEs leading to dose hold

    Time frame: Through participant study completion, approximately Week 56

  21. Number of participants with TEAEs leading to dose modifications

    Time frame: Through participant study completion, approximately Week 56

07

Study locations

13 of 13 sites recruiting
  • Nektar Investigative Site
    Birmingham, Alabama 35203, United States
    Recruiting
  • Nektar Investigative Site
    Oxnard, California 93030, United States
    Recruiting
  • Nektar Investigative Site
    Palmdale, California 93551, United States
    Recruiting
  • Nektar Investigative Site
    Sacramento, California 95815, United States
    Recruiting
  • Nektar Investigative Site
    Tamarac, Florida 33321, United States
    Recruiting
  • Nektar Investigative Site
    Savannah, Georgia 31406, United States
    Recruiting
  • Nektar Investigative Site
    Metairie, Louisiana 70006, United States
    Recruiting
  • Nektar Investigative Site
    Kirksville, Missouri 63501, United States
    Recruiting
  • Nektar Investigative Site
    Lee's Summit, Missouri 64064, United States
    Recruiting
  • Nektar Investigative Site
    Las Vegas, Nevada 89144, United States
    Recruiting
  • Nektar Investigative Site
    Robbinsville, New Jersey 08691, United States
    Recruiting
  • Nektar Investigative Site
    The Bronx, New York 10455, United States
    Recruiting
  • Nektar Investigative Site
    Columbus, Ohio 43213, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jun 2028, 22 months after the start.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's planned 22 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2026
First posted
Jul 17, 2026
StartActual
Aug 7, 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jan 2029
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07711418
Responsible party
Sponsor
First posted
Jul 17, 2026
Start date
Aug 7, 2026
Primary completion
Jun 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Sep 8, 2026

Study contacts

Nektar Recruitment
Contact
StudyInquiry@nektar.com
855-482-8676
Study Director
study director · Nektar Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rezpegaldesleukin

Start the discussion